PerformanceRiskValuationProfitabilityCashflowLiquidityESGRevenue & Geographic ExposureForecastFinancial GrowthIncome GrowthCashflow GrowthBalance Sheet Growth
Tilray Brands, Inc. (TLRY.TO)
2.000.05 (2.56%)
1.90 - 2.15
0.48 - 2.54
9.88M / 3.06M (Avg.)
-0.59 | -3.40
Steady, sustainable growth is a hallmark of high-quality businesses. Value investors watch these metrics to confirm that the company's fundamental performance aligns with—or outpaces—its current market valuation.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
34.84%
EBIT growth of 34.84% while CRON.TO is zero. Bruce Berkowitz would see if small gains can be scaled further.
34.84%
Operating income growth of 34.84% while CRON.TO is zero. Bruce Berkowitz would see if this modest edge can become significant.
34.95%
Net income growth of 34.95% while CRON.TO is zero. Bruce Berkowitz would see if small gains can accelerate into a larger gap.
34.48%
EPS growth of 34.48% while CRON.TO is zero. Bruce Berkowitz would see if minimal gains can accelerate over time.
34.48%
Diluted EPS growth of 34.48% while CRON.TO is zero. Bruce Berkowitz would see if minimal gains can be scaled further for a bigger lead.
0.38%
Share change of 0.38% while CRON.TO is at zero. Bruce Berkowitz would see if slight buybacks (or dilution) matter in the bigger picture.
0.38%
Diluted share change of 0.38% while CRON.TO is zero. Bruce Berkowitz might see a minor difference that could widen over time.
No Data
No Data available this quarter, please select a different quarter.
-1204.92%
Negative OCF growth while CRON.TO is at 0.00%. Joel Greenblatt would demand a turnaround plan focusing on real cash generation.
-1204.92%
Negative FCF growth while CRON.TO is at 0.00%. Joel Greenblatt would demand improved cost control or more strategic capex discipline.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
70.69%
OCF/share CAGR of 70.69% while CRON.TO is zero. Bruce Berkowitz might see a slight advantage that could compound over time.
70.69%
OCF/share CAGR of 70.69% while CRON.TO is zero. Bruce Berkowitz would see if modest momentum can translate into a bigger competitive lead.
70.69%
3Y OCF/share CAGR of 70.69% while CRON.TO is zero. Bruce Berkowitz might see if small gains can expand into a broader advantage.
85.51%
10Y net income/share CAGR of 85.51% while CRON.TO is zero. Bruce Berkowitz would see if minor gains can compound into a bigger lead over time.
85.51%
Net income/share CAGR of 85.51% while CRON.TO is zero. Bruce Berkowitz would see if small mid-term gains can develop into a bigger lead.
85.51%
3Y net income/share CAGR of 85.51% while CRON.TO is zero. Bruce Berkowitz sees if minor improvements can widen to a bigger advantage.
-39.50%
Negative equity/share CAGR over 10 years while CRON.TO stands at 0.00%. Joel Greenblatt sees a fundamental red flag unless the competitor also struggles.
-39.50%
Negative 5Y equity/share growth while CRON.TO is at 0.00%. Joel Greenblatt sees the competitor building net worth while this firm loses ground.
-39.50%
Negative 3Y equity/share growth while CRON.TO is at 0.00%. Joel Greenblatt demands an urgent fix in capital structure or profitability vs. the competitor.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
-37.18%
Firm’s AR is declining while CRON.TO shows 0.00%. Joel Greenblatt sees stronger working capital efficiency if sales hold up.
No Data
No Data available this quarter, please select a different quarter.
-10.91%
Negative asset growth while CRON.TO invests at 0.00%. Joel Greenblatt checks if the competitor might capture more market share unless our returns remain higher.
-7.36%
We have a declining book value while CRON.TO shows 0.00%. Joel Greenblatt sees a fundamental disadvantage in net worth creation vs. the competitor.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
-34.85%
We cut SG&A while CRON.TO invests at 0.00%. Joel Greenblatt sees a short-term margin benefit but wonders if the competitor invests for future gains.